Validity of a point of care device (Cholestech LDX) to monitor liver enzyme activity (aminotransferase measures) during a clinical trial
- PMID: 20430116
- PMCID: PMC2891138
- DOI: 10.1016/j.cct.2010.04.001
Validity of a point of care device (Cholestech LDX) to monitor liver enzyme activity (aminotransferase measures) during a clinical trial
Abstract
Background: Serum transaminase activity is a common measure of liver injury used in clinical trials. The use of a point of care device to monitor serum transaminases would allow immediate evaluation of this safety endpoint and may be less expensive than standard laboratory testing.
Purpose: The objective of this study was to compare a point of care transaminase test to a standard laboratory measurement.
Methods: Subjects were healthy adults participating in a clinical trial measuring the effects of therapeutic doses of acetaminophen on serum transaminase activity. For this study, serum transaminase activity was determined every 3days for 14days. At each measurement, a sample was sent to the clinical laboratory for measurement and also analyzed using a point of care device (Cholestech LDX, Hayward CA). The results were compared using a Bland-Altman plot to identify bias and we also measured the agreement between the techniques for categorizing samples as "low", "normal" or "elevated".
Results: One hundred thirty three samples from 35 subjects were compared. The 95% confidence interval for the limits of agreement between the LDX and the clinical laboratory was -8.46 to 27.09IU/L. Agreement for classification as low, normal or elevated was moderate between the two methods (Kappa=0.37).
Conclusion: The point of care device provided moderate agreement with the laboratory transaminase measurement. However, use of the device would have resulted in misclassification of approximately 1/3 of samples. We do not recommend this point of care device for the measurement of serum transaminases in clinical trials.
Figures



Similar articles
-
A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing.Sci Transl Med. 2012 Sep 19;4(152):152ra129. doi: 10.1126/scitranslmed.3003981. Sci Transl Med. 2012. PMID: 22993296 Free PMC article.
-
Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments.Ann Pharmacother. 2008 May;42(5):633-9. doi: 10.1345/aph.1K688. Epub 2008 Apr 15. Ann Pharmacother. 2008. PMID: 18413684
-
An evaluation of three serum enzyme determinations by manual and multichannel analyzer methods.Am J Clin Pathol. 1972 Nov;58(5):567-78. doi: 10.1093/ajcp/58.5.567. Am J Clin Pathol. 1972. PMID: 4642161 No abstract available.
-
[Aspartate aminotransferase (glutamic oxalacetic transaminase) and alanine aminotransferase (glutamic pyruvic transaminase)].Rinsho Byori. 2001 Nov;Suppl 116:72-80. Rinsho Byori. 2001. PMID: 11797383 Review. Japanese.
-
Liver enzymes, metabolomics and genome-wide association studies: from systems biology to the personalized medicine.World J Gastroenterol. 2015 Jan 21;21(3):711-25. doi: 10.3748/wjg.v21.i3.711. World J Gastroenterol. 2015. PMID: 25624707 Free PMC article. Review.
Cited by
-
Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples.PLoS One. 2015 May 28;10(5):e0128118. doi: 10.1371/journal.pone.0128118. eCollection 2015. PLoS One. 2015. PMID: 26020244 Free PMC article. Clinical Trial.
-
Ambient Ionization Mass Spectrometry Measurement of Aminotransferase Activity.J Am Soc Mass Spectrom. 2017 Jun;28(6):1175-1181. doi: 10.1007/s13361-016-1591-x. Epub 2017 Jan 31. J Am Soc Mass Spectrom. 2017. PMID: 28144898
References
-
- Drug-Induced Liver Injury: Premarketing Clinical Evaluation: United States Food and Drug Administration. 2007 [Accessed 22]; at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
-
- Loten C, Attia J, Hullick C, Marley J, McElduff P. Point of care troponin decreases time in the emergency department for patients with possible acute coronary syndrome: a randomised controlled trial. Emerg Med J. 2010;27:194–198. - PubMed
-
- Cholestech LDX ALT AST Product Insert: Cholestech. 2004 [Accessed 2009]; at http://www.cholestech.com/docs/ldx/ALT-AST.pdf.
-
- Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8:135–160. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources